[Modeling long-term results of basiliximab (SIMULECT) use in patients after kidney transplantation in Great Britain].
Kidney graft survival prognosis could be performed in relation to the number of acute rejection episodes and their severity. The episodes of rejection could be modelled and based and the results obtained on this way could serve for prediction of a length of graft survival as well as for basiliximab treatment planning.
Chilcott
J B
JB
School of Health and Related Research (ScHARR), University of Sheffield, England.
Holmes
M
M
Walters
S
S
Akehurst
R L
RL
D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D000077552:Basiliximab; D006084:Graft Rejection / Q000276:immunology*; D006085:Graft Survival / Q000187:drug effects* / Q000276:immunology; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage*; D016030:Kidney Transplantation / Q000276:immunology*; D008954:Models, Biological; D011379:Prognosis; D016016:Proportional Hazards Models; D011993:Recombinant Fusion Proteins; D012307:Risk Factors; D016019:Survival Analysis
D000911:Antibodies, Monoclonal; D007166:Immunosuppressive Agents; D011993:Recombinant Fusion Proteins; D000077552:Basiliximab